Minimal residual disease negativity was achieved at a significantly higher rate with venetoclax-based therapies, supporting its role in CLL.

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

Lomond Therapeutics Holdings, Inc. ("Lomond Therapeutics"), a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-class and first-in-class medicines for ...

Some CLL patients may receive chemotherapy because of a particular gene mutation or some other circumstance that would keep them from being able to take a targeted therapy safely. Standard ...

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts in white blood cells (called lymphocytes) in the bone marrow. CLL mainly affects older adults and accounts for about one-third of all ...

During a Case-Based Roundtable® event, John N. Allan, MD, discussed how new regimens using BTK inhibitors and venetoclax ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

Venetoclax is a competitor to Imbruvica (ibrutinib) in CLL, which is co-marketed owned ... patients with our without a 17p deletion or TP53 mutation - opening up its use to a much broader group ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Olverembatinib (HQP1351), a novel, next-generation TKI and the first third-generation BCR-ABL1 TKI, has been approved in ...

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions ...

The following grid shows how the soft mutation works.